ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes.
about
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyCIViC databaseAssessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group studyCombined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group StudyTopoisomerase IIβ binding protein 1 c.*229C>T (rs115160714) gene polymorphism and endometrial cancer riskGenetic determinants at the interface of cancer and neurodegenerative disease.Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner.Polymerase ɛ (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing.Targeting lung cancer through inhibition of checkpoint kinases.Genomic analysis of metastatic cutaneous squamous cell carcinoma.Thr-1989 phosphorylation is a marker of active ataxia telangiectasia-mutated and Rad3-related (ATR) kinase.Cyclin-dependent kinase subunit (Cks) 1 or Cks2 overexpression overrides the DNA damage response barrier triggered by activated oncoproteinsMcTwo: a two-step feature selection algorithm based on maximal information coefficient.The genomics and genetics of endometrial cancer.Cell cycle control in acute myeloid leukemia.ATR signalling: more than meeting at the fork.Prognostic Significance of POLE Exonuclease Domain Mutations in High-Grade Endometrioid Endometrial Cancer on Survival and Recurrence: A Subanalysis.Frequent mutations in the RPL22 gene and its clinical and functional implications.Microsatellite instability predicts clinical outcome in radiation-treated endometrioid endometrial cancer.High frequency strand slippage mutations in CTCF in MSI-positive endometrial cancers.Phosphatase and tensin homolog (PTEN) pseudogene expression in endometrial cancer: a conserved regulatory mechanism important in tumorigenesis?Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication.Update on prognostic markers for endometrial cancer.A majority of human melanoma cell lines exhibits an S phase-specific defect in excision of UV-induced DNA photoproducts.Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group StudyEpigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival.Novel SOX17 frameshift mutations in endometrial cancer are functionally distinct from recurrent missense mutations.The mutational spectrum of FOXA2 in endometrioid endometrial cancer points to a tumor suppressor role.MAX Mutations in Endometrial Cancer: Clinicopathologic Associations and Recurrent MAX p.His28Arg Functional Characterization.Next-Generation Sequencing.
P2860
Q26745686-34B705A7-4880-434C-B6EF-F94800910B31Q27612411-AA13316D-8C7D-4686-80D9-6CB8C0FF0EBDQ30356815-C5B99C11-B42E-4944-9DDC-E09B65B43CDBQ30361978-A113573C-5B8F-46AC-870C-6D8866543673Q33775038-42D51CB8-5274-482B-9B49-A54D668924D6Q34422582-BC331471-5979-4917-ABE2-62293246088DQ34676703-BB4B627C-34F1-4F35-A7E0-A6B19382B6AFQ35007615-C5FAD144-2C3B-4104-ADF2-4B93DDD03CF6Q35128547-46129A6B-3B09-475F-BEC7-27FC734FACECQ35178368-2E98E954-EB62-4C83-BDB2-2A0C41A1C484Q35309264-BF86F95E-E58D-4723-9CF3-5553B7ED14F5Q35779036-5B47FBAB-D298-45AE-934D-CE0FCFD012E5Q35967033-735203F5-799C-4064-B261-A9E5AD76D6C9Q36151896-EB1C2C29-347F-4B42-B848-10071B2E78DFQ36206479-661E93D9-7858-4AD4-9166-BCA12103B2EAQ36918246-95EF8281-47B7-46C1-8D7E-A8F61B316131Q36922067-049BA40E-F456-4769-B0E9-8B213E34904AQ37352776-0F44E5FE-6F58-4AC7-B7F5-C09FCC2BB3B9Q37486293-75539E88-E93F-4E0D-B930-63F8A14C31DFQ37624309-83AC7DA7-7E2D-45E1-BA4E-49B33B5DD744Q37638254-061E39F8-B751-4780-AF3A-D9877E61FEADQ37936675-5CD75B91-1E8A-48D1-9772-CAE1B4AE855DQ38222517-4299520E-A896-4F98-B136-C3C8F7BEB6A7Q39035062-207DD546-29F8-47E1-9FA2-E3B447E24EBAQ39668107-14DC2826-545C-4B33-8C1F-2B20265EA982Q41726020-A7800070-0D1D-4309-9C0A-74AD1D3BD2D7Q42366642-065E0975-2B5A-4ED5-8F08-ACE4E2B1CC1CQ42716517-A1B74045-0C11-437E-AEF4-E1E889273D50Q47331699-A5A1326E-B671-4E85-AE9B-43E48C581331Q51032285-A9CB868F-0CB0-4668-86C1-1CB9653FF8F5
P2860
ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
ATR mutation in endometrioid e ...... d with poor clinical outcomes.
@ast
ATR mutation in endometrioid e ...... d with poor clinical outcomes.
@en
ATR mutation in endometrioid e ...... d with poor clinical outcomes.
@nl
type
label
ATR mutation in endometrioid e ...... d with poor clinical outcomes.
@ast
ATR mutation in endometrioid e ...... d with poor clinical outcomes.
@en
ATR mutation in endometrioid e ...... d with poor clinical outcomes.
@nl
altLabel
ATR Mutation in Endometrioid Endometrial Cancer Is Associated With Poor Clinical Outcomes
@en
prefLabel
ATR mutation in endometrioid e ...... d with poor clinical outcomes.
@ast
ATR mutation in endometrioid e ...... d with poor clinical outcomes.
@en
ATR mutation in endometrioid e ...... d with poor clinical outcomes.
@nl
P2093
P2860
P3181
P356
P1476
ATR mutation in endometrioid e ...... d with poor clinical outcomes.
@en
P2093
Amy P Schmidt
David G Mutch
Israel Zighelboim
Janet S Rader
Matthew A Powell
Paul J Goodfellow
Premal H Thaker
Randall K Gibb
P2860
P304
P3181
P356
10.1200/JCO.2008.19.9802
P407
P50
P577
2009-07-01T00:00:00Z